Non-coding RNAs in endometriosis: a narrative review

Panir, Kavita; Schjenken, John E.; Robertson, Sarah A.; Hull, Louise

doi:10.1093/humupd/dmy014

Cited by 121 publications

(99 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 42 ] Deregulation of miRNAs is involved in the pathophysiology of endometriosis and they have been investigated as potential biomarkers. [ 43 ] Agrawal et al analyzed studies of circulating miRNAs in endometriosis in a recent systematic review. [ 44 ] They found that only miR-20 was differentially expressed in multiple studies among 42 different dysregulated miRNAs.…”

Section: New Molecular Signaturesmentioning

confidence: 99%

Current biomarkers for the detection of endometriosis

Tian

Chang

Zhao

et al. 2020

Chinese Medical Journal

View full text Add to dashboard Cite

A clinically reliable non-invasive test for endometriosis is expected to reduce the diagnostic delay. Although varieties of biomarkers have been investigated for decades, and cancer antigen-125, cancer antigen-199, interleukin-6, and urocortin were the most studied ones among hundreds of biomarkers, no clinically reliable biomarkers have been confirmed so far. Some emerging technologies including “omics” technologies, molecular imaging techniques, and microRNAs are promising in solving these challenges, but their utility to detect endometriosis has yet to be verified. New combinations of researched indicators or other non-invasive methods and further exploration of the emerging technologies may be new targets and future research hotspots for non-invasive diagnosis of endometriosis. In conclusion, researches of biomarkers for the detection of endometriosis are still ongoing and may benefit from novel molecular biology, bioinformatics methods and a combination of more diverse monitoring methods. Though it will be a daunting task, the identification of a specific set of diagnostic biomarkers will undoubtedly improve the status of endometriosis.

show abstract

Section: New Molecular Signaturesmentioning

confidence: 99%

Current biomarkers for the detection of endometriosis

Tian

Chang

Zhao

et al. 2020

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…MicroRNAs, particularly circulating microRNAs, have been found to be highly stable with long half-lives under a controlled environment [47,48]. Accumulating evidence from studies across broad biomedical disciplines suggests the involvement of microRNAs, and their potential applications as diagnostic as well as prognostic biomarkers in various human diseases including cancer [49][50][51], neurodegenerative diseases [52][53][54][55], fertility disorders [56,57], and metabolic disorders [58,59]. For several years, our research effort has been devoted to discovering potential applications of microRNAs in disease diagnosis, as well as elucidating the role of dysregulated microRNAs in cardiovascular pathogenesis [60][61][62][63][64].…”

Section: Micrornas the Small Nucleotides That May Play Big Roles In mentioning

confidence: 99%

Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs

Chen

Wong

Liew

et al. 2019

Cells

View full text Add to dashboard Cite

Circulating microRNAs offer attractive potential as epigenetic disease biomarkers by virtue of their biological stability and ready accessibility in liquid biopsies. Numerous clinical cohort studies have revealed unique microRNA profiles in different disease settings, suggesting utility as markers with diagnostic and prognostic applications. Given the complex network of microRNA functions in modulating gene expression and post-transcriptional modifications, the circulating microRNA landscape in disease may reflect pathophysiological status, providing valuable information for delineating distinct subtypes and/or stages of complex diseases. Heart failure (HF) is an increasingly significant global health challenge, imposing major economic liability and health care burden due to high hospitalization, morbidity, and mortality rates. Although HF is defined as a syndrome characterized by symptoms and findings on physical examination, it may be further differentiated based on left ventricular ejection fraction (LVEF) and categorized as HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). The presenting clinical syndromes in HFpEF and HFrEF are similar but mortality differs, being somewhat lower in HFpEF than in HFrEF. However, while HFrEF is responsive to an array of therapies, none has been shown to improve survival in HFpEF. Herein, we review recent HF cohort studies focusing on the distinct microRNA profiles associated with HF subtypes to reveal new insights to underlying mechanisms and explore the possibility of exploiting these differences for diagnostic/prognostic applications.

show abstract

“…Till now, the gold standard of diagnosis of EM was laparoscopic visualization, ideally with histological verification (Zondervan et al 2018). In EM, miRNAs play an emerging important role and many researches have explored the clinical applications of miRNA-based therapeutics (Panir et al 2018). MicroRNA has also been studied as a potential diagnostic marker of EM (Nisenblat et al 2016) since the presence of altered miRNA profiles in the plasma was reported in several types of solid tumors, such as ovarian cancer (Taylor & Gercel-Taylor 2008), and other diseases.…”

Section: Discussionmentioning

confidence: 99%

Genome-wide profiling of miRNA expression patterns in tubal endometriosis

Qi¹,

Guo²,

Yu³

et al. 2019

Reproduction

View full text Add to dashboard Cite

MicroRNA (miRNA) expression proﬁles in tubal endometriosis (EM) are still poorly understood. In this study, we analyzed the differential expression of miRNAs and the related gene networks and signaling pathways in tubal EM. Four tubal epithelium samples from tubal EM patients and five normal tubal epithelium samples from uterine leiomyoma patients were collected for miRNA microarray. Bioinformatics analyses, including Ingenuity Pathway Analysis (IPA), Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, were performed. Quantitative real-time polymerase chain reaction (qRT-PCR) validation of five miRNAs was performed in six tubal epithelium samples from tubal EM and six from control. A total of 17 significantly differentially expressed miRNAs and 4343 potential miRNA-target genes involved in tubal EM were identified (fold change >1.5 and FDR-adjusted P value <0.05). IPA indicated connections between miRNAs, target genes and other gynecological diseases like endometrial carcinoma. GO and KEGG analysis revealed that most of the identified genes were involved in the mTOR signaling pathway, SNARE interactions in vesicular transport and endocytosis. We constructed an miRNA-gene-disease network using target gene prediction. Functional analysis showed that the mTOR pathway was connected closely to tubal EM. Our results demonstrate for the first time the differentially expressed miRNAs and the related signal pathways involved in the pathogenesis of tubal EM which contribute to elucidating the pathogenic mechanism of tubal EM-related infertility.

show abstract

Non-coding RNAs in endometriosis: a narrative review

Cited by 121 publications

References 180 publications

Current biomarkers for the detection of endometriosis

Current biomarkers for the detection of endometriosis

Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs

Genome-wide profiling of miRNA expression patterns in tubal endometriosis

Contact Info

Product

Resources

About